For the year ending 2025-12-31, COEPW had $5,141,417 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -12,277,192 |
| Depreciation and amortization | 1,181,212 |
| Right of use asset amortization | 41,385 |
| Amortization of debt discount | 545,635 |
| Non-cash revenue | 1,333,045 |
| Stock based compensation | 1,215,692 |
| Shares issued for non-employee services | 3,829,220 |
| Warrants issued for services | 824,295 |
| Change in fair value of derivative liability | 906,430 |
| Change in fair value of derivative liability warrants | -191,625 |
| Loss on shares issued for conversion of debt | 0 |
| (gain) loss on extinguishment of debt | 159,035 |
| Forgiveness of interest | 0 |
| Unrealized loss on investments | -163,500 |
| Unrealized gain on marketable securities | 76,596 |
| Interest receivable | 7,348 |
| Prepaid assets | 473,497 |
| Accounts payable | -381,012 |
| Accrued expenses | -440,889 |
| Right of use liability | -42,306 |
| Other current liabilities | -115,000 |
| Net cash used in operating activities | -8,603,036 |
| Net cash used in investing activities | 0 |
| Proceeds from notes payable | 990,000 |
| Repayment of notes payable | -218,750 |
| Shares issued for sepa | 2,958,848 |
| Shares issued for cash | 4,558,455 |
| Warrants issued for cash | 0 |
| Pre-funded warrants exercise | 900 |
| Preferred stock offering | 5,455,000 |
| Net cash provided by financing activities | 13,744,453 |
| Net increase (decrease) in cash | 5,141,417 |
| Cash at beginning of period | 532,885 |
| Cash at end of period | 5,674,302 |
Coeptis Therapeutics Holdings, Inc. (COEPW)
Coeptis Therapeutics Holdings, Inc. (COEPW)